This K24 Career Development Award will allow me to continue my efforts to """"""""translate"""""""" tumor immunology from the laboratory into the clinic to improve therapy of adult solid tumors. These efforts will apply immune-based treatments to genitourinary cancers (especially prostate) and melanoma. The trials will be based on strong scientific rationale, require collaborations with laboratory scientists, require an appropriate patient base, and incorporate laboratory and immunologic endpoints in addition to standard clinical endpoints. The clinical research program will be directed towards three major objectives: 1. developing and testing immunotherapeutic approaches for Prostate Cancer; 2. continue to study Melanoma biology and develop novel therapeutic approaches to this disease. Therapies to be tested may extend beyond solely immune-based approaches and will include active participation at all levels (institutional, multi-institutional, and large cooperative group) of trial design and implementation; and 3. continue efforts to make the Cytokine Working Group (CWG) an NCI funded cooperative group in Tumor Immunotherapy by becoming a mechanism to rapidly and creatively test more complex immune oriented approaches primarily in phase II trials. The mentoring of beginning clinical investigators is a critical component of the K24 and will be focused on bringing junior faculty and/or Hematology/Oncology fellows into one of several areas of training with well defined responsibilities and educational programs. These include: 1. the Tumor Immunotherapy Program emphasizing pre-clinical, laboratory work, incorporation of immune monitoring into clinical trial design, and protocol preparation and implementation; 2. Genitourinary (GU) Cancer Multidisciplinary Program with an emphasis on prostate immunotherapy; and 3. As the Director of Clinical Research within the Section of Hematology/Oncology provide an introduction to clinical trials research including an overview of faculty expertise and how to initiate clinical investigation with one of the faculty. Furthermore, I will act as a consultant for their clinical research. By combining my efforts to merge laboratory efforts and immunologic endpoints with strong clinical trial design, I believe clinical research can better move tumor immunotherapy forward in a more rationale way.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24CA097588-02
Application #
6640488
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
2002-02-15
Project End
2007-01-31
Budget Start
2003-06-06
Budget End
2004-01-31
Support Year
2
Fiscal Year
2003
Total Cost
$134,379
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Moriceau, Gatien; Hugo, Willy; Hong, Aayoung et al. (2015) Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27:240-56
Cohen, Daniel N; Lawson, Steven K; Shaver, Aaron C et al. (2015) Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. Clin Cancer Res 21:2624-34
Hutchinson, Katherine E; Ross, Jeffrey S; Stephens, Philip J et al. (2014) Melanoma BRAF fusions--response. Clin Cancer Res 20:6632
Meador, Catherine B; Micheel, Christine M; Levy, Mia A et al. (2014) Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 20:2264-75
Johnson, Douglas B; Smalley, Keiran S M; Sosman, Jeffrey A (2014) Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res 20:4186-92
Xia, Junfeng; Jia, Peilin; Hutchinson, Katherine E et al. (2014) A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol Cancer Ther 13:1918-28
Shi, Hubing; Hugo, Willy; Kong, Xiangju et al. (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4:80-93
Haq, Rizwan; Fisher, David E; Widlund, Hans R (2014) Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res 20:2257-63
Kim, Kevin B; Kefford, Richard; Pavlick, Anna C et al. (2013) Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482-9
Hutchinson, Katherine E; Lipson, Doron; Stephens, Philip J et al. (2013) BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 19:6696-702

Showing the most recent 10 out of 34 publications